C$0.90 pre-market 23 Mar 2026: Healwell AI (AIDX.TO TSX) Q4 revenue up, watch targets

Healwell AI Inc. (AIDX.TO stock) opens pre-market at C$0.90 on 23 Mar 2026 after reporting a Q4 revenue surge. The company reported revenue of C$32.20 million for Q4, a 374.00% year-over-year increase that reshapes near-term cash flow expectations. Investors must weigh that growth against a negative EPS of -C$0.23 and a price-to-sales ratio of 2.28. We examine the Q4 drivers, key ratios, technical signals, and our scenario-based price targets for this TSX-listed healthcare AI name.

AIDX.TO stock: pre-market snapshot

AIDX.TO stock trades on the TSX in Canada at C$0.90 with a day range C$0.88–C$0.94 and volume 354,239 shares. The company’s market cap is C$225,502,192 and shares outstanding are 278,397,768. The 50-day average price is C$0.80 and the 200-day average is C$1.15, showing short-term support below the longer-term trend. Key headline ratios include EPS -C$0.23 and PE -3.52, reflecting current losses despite revenue growth.

Q4 results and AIDX.TO stock news

Healwell reported Q4 revenue of C$32.20 million, up 374.00%, and discussed the quarter on its earnings call. Management highlighted customer onboarding and product uptake as the revenue drivers. Read the earnings call transcript on Seeking Alpha for the management commentary and detail source. Market coverage of the results included a summary noting the revenue jump and guidance change source.

Financials, valuation and AIDX.TO analysis

On fundamentals, revenue per share is C$0.42 and book value per share is C$0.52. The price-to-sales ratio is 2.28 and the price-to-book is 1.62. Cash per share is C$0.07 and the current ratio is 0.85, signaling tight short-term liquidity. Debt-to-equity stands at 0.74, and operating cash flow per share is -C$0.10. These metrics show growth but persistent negative margins and cash flow pressure, important for AIDX.TO stock investors to weigh against topline momentum.

Technicals and trading flow for AIDX.TO stock

Momentum indicators are mixed: RSI 47.64 sits near neutral, MACD 0.04 with a flat histogram, and ADX 38.18 shows a strong trend. Bollinger Bands are Upper C$1.05 and Lower C$0.59, implying room for volatility. On balance volume is negative and average volume 563,025 exceeds current daily pace, suggesting attention from traders. Price action over 1M is up 30.65%, while 6M is down 43.75%, highlighting event-driven swings in AIDX.TO stock trading.

Meyka Grade and AIDX.TO stock forecast

Meyka AI rates AIDX.TO with a score of 62.02 out of 100 (Grade: B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of C$0.65, a quarterly price of C$0.72, and a yearly price of C$0.40. Versus the current C$0.90, that implies downside of -27.78%, -20.00%, and -55.62%, respectively. Forecasts are model-based projections and not guarantees.

Risks, catalysts and AIDX.TO stock outlook

Primary catalysts include continued client growth, product deployments, and deeper WELL Health partnership integration. Major risks are low liquidity, negative cash flow, and a company rating of D+ from third-party scorers dated 2026-03-20, which flags valuation and profitability concerns. Sector context matters: Healthcare names in Canada have shown weak 6M performance, so AIDX.TO stock remains sensitive to sector flows and funding waves for AI health startups.

Final Thoughts

Key takeaways for AIDX.TO stock investors: Healwell AI posted a C$32.20 million Q4 and strong revenue growth, yet the stock trades at C$0.90 with negative EPS -C$0.23 and constrained liquidity (current ratio 0.85). Our scenario price targets: a conservative base case C$0.75 (down -16.67%), a bear case C$0.45 (down -50.00%), and a bull case C$1.40 (up 55.56%) based on faster commercial adoption. Meyka AI’s model projects monthly C$0.65 and yearly C$0.40, implying material downside and underscoring execution risk. Investors focused on AI stocks should weigh the revenue momentum against cash flow and rating headwinds. For a live data view and charting, see AIDX.TO on Meyka AI’s platform as an AI-powered market analysis platform and track updates closely

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.